Short‐Term Weight Loss Outcomes of 1.0 mg Semaglutide Therapy Initiated 6 Months After Sleeve Gastrectomy

Sep 18, 2025Obesity (Silver Spring, Md.)

Short-Term Weight Loss After Starting 1.0 mg Semaglutide Six Months Following Sleeve Gastrectomy

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Patients receiving semaglutide after laparoscopic sleeve gastrectomy lost 14.03 kg more weight than controls over 6 months.

Both treatment and control groups achieved substantial total weight loss of approximately 23% at 6 months post-surgery.
From 6 to 12 months, the treatment group experienced significantly greater absolute weight loss compared to the control group.
Percentage weight loss from 6 to 12 months was also significantly higher in the treatment group than in controls.
At 12 months, total weight loss was notably greater in the semaglutide group compared to those not receiving the medication.

AI simplified

OBJECTIVE: This study aimed to evaluate the weight loss efficacy of semaglutide initiated 6 months after laparoscopic sleeve gastrectomy (LSG).

METHODS: This retrospective study included patients undergoing primary LSG. Patients receiving semaglutide (1.0 mg weekly) at 6 months post LSG for 6 months were matched 1:3 with controls not receiving semaglutide, balancing demographics, preoperative BMI, waist-hip ratio, comorbidities, and total weight loss (TWL) at 6 months post surgery. Primary outcomes were absolute and percentage weight loss from 6 to 12 months post LSG.

RESULTS: Both the treatment (n = 34) and control (n = 102) groups achieved substantial TWL (23.16% ± 6.50% vs. 23.53% ± 4.87%) at 6 months post LSG. From 6 to 12 months, the treatment group experienced significantly greater absolute (14.03 ± 5.26 kg vs. 5.63 ± 6.25 kg; p < 0.0001) and percentage (12.61% ± 4.11% vs. 4.84% ± 5.18%; p < 0.0001) weight loss than controls. At 12 months, TWL was also higher in the treatment group (35.77% ± 8.35% vs. 28.37% ± 7.41%; p < 0.0001).

CONCLUSIONS: Semaglutide initiated 6 months post LSG significantly enhances short-term postoperative weight loss, even among patients who have already achieved substantial initial weight loss. These findings suggest its potential as an effective adjunct therapy for optimizing weight management in early postoperative care.

Full Text

Full text is available at the source.

View full text ↗

Short‐Term Weight Loss Outcomes of 1.0 mg Semaglutide Therapy Initiated 6 Months After Sleeve Gastrectomy

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief